Member Info for Vander

Btw in answer to my own question: If the focus is customisation to hsv pDNA for example they will want to adjust the manufacturing conditions for example wrt temperature/time etc and then assess particle characteristics produced ie size, pore size, nanotypography (the spikes) which they assess with TEM. Ultimately they will then assess whether loading and transfection to cells is as good as it can be. I am presuming they are not waiting for the results of more animal research which will take up to 1-2 years They will want to know that nuvec can be manufactured reliably This corresponds to phase 1 of UoA ie 4 weeks plus time for repeat experimentation and then negotiation and planning. Xmas gets in the way What do others think re timescale? I realise some are also questioning whether there will be a deal. Melody will be disappointed

It’s ok those guys will be back The SP goes up and then down- it’s hard to remember what the rns was about Oh yes- a deal with medimmune Also a patent And melody Janssen has been drafted in- she dealt with the big deal offered to mymetics by astellas 2014-6 It’s good that medimmune are committed’ to developing alternatives to npls and viral vectors. By optimised version of nuvec, I believe they mean customised to their particular product- presumably directed against herpes simplex virus (hsv). It’s possible that they will want to deliver mRNA or pDNA- they will want to ensure adequate loading and delivery and then start small animal and large animal work using their significant resources. When will the deal be struck?

AL was previously a team leader with medimmune and now an independent consultant, who was working part time with N4p Melody was head of preclinical research with Mymetics 2014-16, at the time they had a collaboration with a subsidiary of Astellas (large Japanese Pharma) their deal was 5m upfront with up to 80m in milestones, using virosomes to deliver a vaccine for RSV (a childhood viral infection)- mucosally mediated. That deal ended after two years when Astellas pulled out Melody seems experienced and well suited to the job

My average is 24p but not a very big amount. I do not want to disrupt the SP for honest shareholders here who have a lot invested financially and emotionally. I think that something should be said though I will not post again- unless there is something to ramp. I want the SP to go up but not at the expense of honesty. I am not here to coral other mugs

The problem is we want the SP to go up and so it is difficult to mention these things. Maybe we can keep these things in the back of our minds dependent on the course of events. Surely some of you guys are in security/ police?

Do you think the Dec 23rd rns presented an honest depiction of company prospects given that the highly lucrative contract which was announced in numerate detail was with a country which was also on the cusp of well signposted US sanctions. Also it was announced when the company were in need of funds and there was a maelstrom of excitement that the unknown country was Oman which was to announce opening arrangements coinciding with the phases mentioned in the rns

Do you think it was a coincidence that the announcement of the placing was made on the same day as the announcement of the muscat airport opening date?

There was a placing announced by rns on 31st Jan 2018. Interestingly this coincided on the same day of announcement of the opening date of Oman airport. The placing was taken up avariciously Soon after this there was promotional video released by OMAC in which people believed that they saw PF in a line of dignitaries wearing a luminous yellow jacket, approx 23 minutes in

How does brexit affect N4p specifically? Will it affect Eu ncl? It may affect general risk aversion and uk exposed stocks prices are affected Will it affect AZ and big Pharma investment in uk or its biotech SMEs?

evidence of a multi billion company, in this case delivering mRNA and proteins. Collaborations with big Pharma, but no marketed product yet they use liposomes- hence relevant to us Their products are all in preclinical and human trials but they have secured billions in funding

Different strands of nuvec development are coming together. We are in the process of becoming a fully formed product. It would be worth revisiting NTs presentation on pros and cons vs NPLs. I think he only mentions the pros though. We get market space in a multi billion market we will do well Imho

Sorry- nucleic acids

This good. The are first movers with this type of delivery system for nucleus acids and need to protect the IP. Not surprising that industrial manufacture should be ok. Medimmune would not be continuing collaboration unless all near term goals/challenges likely to be met

Thanks leister Are their vaccines all formulated with liposomes? GSK are using lipofoam with shingrix

I agree with aimchaos summary. Regarding whether it is the most exciting share on aim- I presume he does not say that to every share he meets

I didn’t show any concern. I am a ramper

Thanks- please contact nigel

Oh no taffevans the N4p millionaire is back

Nice

Hi Chelsea How do we identify a bull flag?